Adverse events associated with donor plateletpheresis: A 10-year experience from Vojvodina, Serbia

  • Zorana Budakov Obradović Blood Transfusion Institute Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Nevenka Bujandrić Blood Transfusion Institute Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Jasmina Grujić Blood Transfusion Institute Vojvodina, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Keywords: blood donors;, drug-related side effects and adverse reactions;, plateletpheresis;, risk factors.

Abstract


Background/Aim. Plateletpheresis (PLTP) is a medical procedure used for collecting donor platelets with multiple benefits for patients who will receive apheresis platelets. The procedure takes one hour and is well tolerated by donors. Nevertheless, adverse events (AEs) may occur during and after the PLTP procedure. The aim of the study was to determine the incidence and type of AEs associated with PLTP in donors. Methods. A retrospective analysis of AEs associated with donor PLTP was conducted at the Blood Transfusion Institute of Vojvodina from January 1, 2010, to December 31, 2019. Results. Out of 2,073 platelet donors, 94.84% were multiple blood donors, predominantly male (98.55%). AEs were identified during 180 (8.68%) platelet donations with no statistical significance in occurrence in the first time donors (10.28%) and repeat donors (8.59%). Mild local reactions related to venous access (42.22%) were the most common AEs. Generalized symptoms were exhibited in 16.67% of donors, 26.11% exhibited symptoms related to apheresis (citrate reactions), and 15% exhibited those related to other complications. It was found that 95.55% of AEs occurred during PLTP and only 4.45% after it. Conclusion. Donor PLTP is a generally safe procedure, well tolerated by donors. Understanding risk factors for a possible occurrence of AEs provides support for adopting measures to prevent them.

References

Dogu MH, Hacioglu S. Analysis of plateletpheresis donor defer-ral rate, characteristics, and its preventability. J Appl Hematol 2017; 8: 12‒5.

Kaufman RM, Đulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162(3): 205‒13.

Estcourt LJ, Malouf R, Hopewell S, Doree C, Van Veen J. Use of platelet transfusions prior to lumbar punctures or epidural an-aesthesia for the prevention of complications in people with thrombocytopenia. Cochrane Database Syst Rev 2018; 4: CD011980.

Squires JE. Indications for platelet transfusion in patients with thrombocytopenia. Blood Transfus 2015; 13(2): 221–6.

Ferber T, Hannan M. Donor Apheresis. In: Linz W, Chhibber V, Hoffman J, Torloni A, Vrielink H, Mason H, et al, editors. Principles of Apheresis Technology: Technical Principles of Apheresis Medicine. 6th ed. BC. Vancouver, BC: ASFA; 2017. p. 143‒62.

Grujic J, Gulan Z, Budakov Z. Importance of hemovigilance and reports on transfusion reaction in blood component therapy. Med Pregl 2012; 65(1‒2): 50‒3. (Serbian)

Heuft HG, Fischer E, Weingand T, Burkhardt T, Leitner G, Baume H, et al. Donor Safety in Haemapheresis: Development of an Internet-Based Registry for Comprehensive Assessment of Adverse Events from Healthy Donors. Transfus Med Hemother 2017; 44(3): 188‒200.

Standard for Surveillance of Complications Related to Blood Donation. Working Group on Donor Vigilance of the Interna-tional Society of Blood Transfusion (ISBT); Working Party on Hemovigilance in collaboration with The International Hae-movigilance Network and The American Association of Blood Banks (AABB) Donor Hemovigilance Working Group, De-cember 11, 2014. Available from: http://www.aabb.org/rese

arch/hemovigilance/Documents/Donor-Standard-Definitions

.pdf.

Goldman M, Land K, Robillard P, Wiersum-Osselton J. Develop-ment of standard definitions for surveillance of complications related to blood donation. Vox Sang 2016; 110(2): 185‒8.

Das SS, Sen S, Chakrabarty RI. Machine and man individuali-ties in apheresis adverse events. Global J Trans Med 2018; 3(1): 30‒3.

Bialkowski W, Bruhn R, Edgren G, Papanek P. Citrate antico-agulation: Are blood donors donating bone? J Clin Apher 2016; 31(5): 459–63.

Low on I transfusion medicine. ("Sl. glasnik RS", br. 40/17, 113/17).

Guan L, Tian X, Gombar S, Zemek AJ, Krishnan G, Scott R, et al. Big data modeling to predict platelet usage and minimize wastage in a tertiary care system. Proc Natl Acad Sci USA 2017; 114(43): 11368‒73.

Yu C, Lau JT, Zhong W, Huang X, Pan C, Chen Y, et al. Why some donors are more willing to donate platelets? – a qualita-tive study on 25 regular platelet donors in Guangzhou, China. BMC Public Health 2019; 19(1): 1671.

Estcourt JL, Birchall J, Allard S, Bassey JS, Hersey P, Kerr JP, et al. British Committee for Standards in Haematology. Guide-lines for the use of platelet transfusions. Br J Haematol 2017; 176(3): 365‒94.

Khajuria K, Sawhney V, Sharma R, Gupta S. Adverse donor re-action during and after plateletpheresis in a tertiary care cen-tre. Int J Res Med Sci 2017; 5(4): 1221‒3.

Diekamp U, Gneißl J, Rabe A, Kießig ST. Donor Hemovigilance with Blood Donation. Transfus Med Hemother 2015; 42(3): 181–92.

Navkudkar A, Desai P, Rajadhyaksha S. Effect of citrate on ionized calcium levels during plateletpheresis procedures. Vox Sang 2021; 16(1): 26–30.

Dogra K, Fulzele P, Rout D, Chaurasia R, Coshic P, Chatterjee K. Adverse Events During Apheresis Procedures: Audit at a Ter-tiary Hospital. Indian J Hematol Blood Transfus 2017; 33(1): 106‒8.

Shanthi B, Sudhir Kumar V, Mahesh K, Krishna BM. Adverse Events Associated with Plateletpheresis: A Tertiary Care Hos-pital Experience in Southern India. J Clin Diagn Res 2019; 13(5): EC10‒EC12.

Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci 2013; 7(1): 37–41.

Bassi R, Thakur KK, Bhardwaj K. Plateletpheresis adverse events in relation to donor and plateletpheresis session profile. Iraqi J Hematol 2017; 6: 38–42.

Published
2022/09/22
Section
Original Paper